Who makes MnB vaccine rLP8026?

MnB vaccine rLP8026 is developed by Wyeth is now a wholly owned subsidiary of Pfizer.

What development phase is MnB vaccine rLP8026 in?

MnB vaccine rLP8026 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

MnB vaccine rLP8026

Wyeth is now a wholly owned subsidiary of Pfizer · Phase 1 active Biologic

At a glance

Generic name	MnB vaccine rLP8026
Sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MnB vaccine rLP8026 CI brief — competitive landscape report
MnB vaccine rLP8026 updates RSS · CI watch RSS
Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI